Respiratory Syncytial Virus

Disease State Hub

Featured

Respiratory Diseases Roundup

Nirmatrelvir-Ritonavir Lacks Benefit for Patients With Long COVID, CDC Updates Recommendations for “Triple Threat” Vaccines, and More

10/24/2024

Anthony Calabro, MA

In this respiratory disease roundup, researchers report on the efficacy of nirmatrelvir-ritonavir for treating Long COVID, the CDC updates recommendations on “triple threat” vaccines for respiratory virus...

10/24/2024

Conference Coverage

Conference Coverage

Risk Factors Associated With Prolonged Hospital Length of Stay in Adult Patients With RSV

10/13/2024

Ashish Bhargava, MD

In this video, Ashish Bhargava, MD, discusses the results of his team's study on the risk factors associated with a longer hospital stay in adult patients with respiratory syncytial virus (RSV. He talks...

10/13/2024

Conference Coverage

Conference Coverage

Annual Conference on Vaccinology Research: Challenges, Breakthroughs, and the Future of Vaccines

05/02/2024

William Schaffner, MD

In this video, William Schaffner, MD, provides an overview of the topics presented at the 2023 Annual Conference on Vaccinology Research, hosted by the National Foundation for Infectious Diseases, including...

05/02/2024

Clinical Insights

Conference Coverage

Risk Factors Associated With Prolonged Hospital Length of Stay in Adult Patients With RSV

10/13/2024

Ashish Bhargava, MD

10/13/2024

Conference Coverage

Annual Conference on Vaccinology Research: Challenges, Breakthroughs, and the Future of Vaccines

05/02/2024

William Schaffner, MD

05/02/2024

Expert Q&A

Bivalent Prefusion F Vaccine For Older Adults

03/18/2024

The FDA approved the use of Pfizer’s bivalent prefusion f vaccine in older adults to protect against respiratory syncytial virus. A Pfizer spokesperson answered questions about the study that helped lead to...

03/18/2024

Expert Q&A

Use of Prefusion F Vaccine in Pregnant Women to Prevent RSV in Infants

03/18/2024

Are there benefits to vaccinating women who are pregnant with a vaccine that prevents respiratory syncytial virus (RSV)-related illness in newborns? A new study examined this topic.

03/18/2024

Conference Coverage

Conference Coverage

Social Risk Factors Associated With Older Adults Hospitalized For RSV-Related Illnesses

03/05/2024

Khalel De Castro • Ashley Tippett, MPH, MLS(ASCP)cm • Christina A. Rostad, MD

Khalel De Castro • Ashley Tippet...

In this video, Ashley Tippett, MPH, MLS(ASCP)cm, Khalel De Castro, and Christina A. Rostad, MD, speak about the social risk factors associated with older adults diagnosed with respiratory syncytial virus...

03/05/2024

Respiratory Syncytial Virus Snapshot

For more viral infections content, visit the Disease State Hub

Respiratory syncytial virus (RSV) is a common respiratory virus that typically causes mild symptoms, similar to a cold. Most people recover within 1 to 2 weeks, but it can be serious for infants and older adults.

For pulmonary disorders content, visit the Disease State Hub

Pulmonologists, Infectious Disease Specialists, Primary Care, Pediatricians, Geriatricians

People show symptoms within 4 to 6 days after infection, and symptoms typically appear in stages, rather than all at once.

Symptoms include: rhinorrhea (runny nose), decrease in appetite, coughing, sneezing, fever, and wheezing

For diagnosis strategies content, visit the Resource Center

Testing is not typically required, as the symptoms are similar to a cold. A physician may run tests, such as a mouth swab or blood test to check white blood cell count and the presence of viruses.

For public health content, visit the Resource Center

Globally, RSV affects 64 million people each year and causes 160,000 deaths annually. The virus is the most common cause of bronchiolitis (inflammation in the small airways of a person's lungs).

For critical care content, visit the Resource Center

RSV sends approximately 58,000 children aged 5 years or younger to hospitals for treatment every year. For the same population, 100 to 300 deaths can occur each year due to RSV. *United States data

For intensive care medicine content, visit the Resource Center

RSV in older adults results in 60,000 to 160,000 hospitalizations each year and approximately 6,000 to 10,000 adults aged 65 years or older die from the virus. *United States data

Research Summaries

Respiratory Diseases Roundup

Nirmatrelvir-Ritonavir Lacks Benefit for Patients With Long COVID, CDC Updates Recommendations for “Triple Threat” Vaccines, and More

10/24/2024

Anthony Calabro, MA

10/24/2024

Research Summary

ACIP Releases 2024 Adult Immunization Schedule

03/26/2024

Jessica Ganga

The Advisory Committee on Immunization Practices released its updated annual immunization schedule for 2024 that includes new sections on respiratory syncytial virus (RSV), and the mpox (monkeypox) and...

03/26/2024

Research Summary

CDC Updates Guidance on Respiratory Viruses, Ends 5-Day Isolation Period For Those Recovering From COVID-19

03/05/2024

Anthony Calabro, MA

The CDC updated its guidance due to the United States seeing fewer hospitalizations associated with COVID-19 and because there are numerous tools to combat influenza, COVID-19, and respiratory syncytial...

03/05/2024

COVID-19 Roundup

FDA Releases Guidance on Moderna Vaccine Dosage, Association of COVID-19 and RSV With Pediatric Patients, and More

01/17/2024

Jessica Ganga

This COVID-19 roundup includes coverage of the FDA’s guidance for the correct Moderna vaccine dosage for pediatric patients, COVID-19 outcomes for patients with hypertension and diabetes, and the risk of...

01/17/2024

FDA Alert

FDA Approves First RSV Vaccine For Pregnant Individuals

08/24/2023

Anthony Calabro, MA

Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

08/24/2023

October 2024

Current Issue

October 2024

Volume 64

Issue 9

Sources: